Weill Cornell Medicine has been awarded a five-year, $11.3 million Specialized Programs of Research Excellence (SPORE) grant from the National Cancer Institute to improve the detection, diagnosis, and treatment of prostate cancer.

Searching for approaches to address ongoing challenges, a number of studies and clinical trials are evaluating new approaches for neoadjuvant therapies and early phase clinical trials to assess novel therapeutic agents based on tumor genomics.

In the past 50 years, use of neoadjuvant chemotherapy for breast cancer has evolved. Today, clinicians at NewYork-Presbyterian are using neoadjuvant therapy to tackle residual tumor.

Surgeons at NewYork-Presbyterian/Columbia are turning up the heat (or cold as the case may be) on early-stage breast cancer tumors with the use of ablation therapies.